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One of the major regulators of mitosis in somatic cells
is cdc25B. cdc25B is tightly regulated at multiple levels.
The final activation step involves the regulated binding
of 14-3-3 proteins. Previous studies have demonstrated
that Ser-323 is a primary 14-3-3 binding site in cdc25B,
which influences its activity and cellular localization.
14-3-3 binding to this site appeared to interact with the
N-terminal domain of cdc25B to regulate its activity.
The presence of consensus 14-3-3 binding sites in the
N-terminal domain suggested that the interaction is
through direct binding of the 14-3-3 dimer to sites in the
N-terminal domain. We have identified Ser-151 and Ser-
230 in the N-terminal domain as functional 14-3-3 bind-
ing sites utilized by cdc25B in vivo. These low affinity
sites cooperate to bind the 14-3-3 dimer bound to the
high affinity Ser-323 site, thus forming an intramolecu-
lar bridge that constrains cdc25B structure to prevent
access of the catalytic site. Loss of 14-3-3 binding to
either N-terminal site relaxes cdc25B structure suffi-
ciently to permit access to the catalytic site, and the
nuclear export sequence located in the N-terminal do-
main. Mutation of the Ser-323 site was functionally
equivalent to the mutation of all three sites, resulting in
the complete loss of 14-3-3 binding, increased access of
the catalytic site, and access to nuclear localization
sequence.
The partitioning of the replicated genome in mitosis must
occur with high fidelity or else the outcome will be an unequal
complement of chromosomes in each of the daughter cells. This
genomic instability may result in loss of growth suppressors or
gain to growth promoters, with a potential for dysregulation of
normal growth controls and possibly neoplastic transforma-
tion. Thus mechanisms controlling entry into and progression
through mitosis must be tightly controlled to ensure the fidelity
of this critical process. In all eukaryotes, entry into mitosis is
regulated by the activation of cdc2/cyclin B. In higher eu-
karyotes, the activation of cdc2/cyclin B is controlled not only
temporally but spatially. cdc2/cyclin B1 accumulates as an
inactive complex in the cytoplasm during G2 phase. The initial
evidence of mitosis is a change in microtubule dynamics and
increased microtubule nucleation at the centrosomes. This cor-
responds to activation of cdc2/cyclin B1 in cytoplasm and at the
centrosomes in prophase of mitosis, and occurs before any
noticeable mitotic changes occur in the nucleus (1, 2). Activated
cdc2/cyclin B1, and the remaining inactive cdc2/cyclin B1 are
translocated into the nucleus, where the latter pool is activated
and full mitotic phenotype is observed. The activation of cdc2/
cyclin B in mitosis is regulated by the removal of inhibitory
phosphorylations from Thr-14 and Tyr-15 residues in cdc2,
catalyzed by the cdc25 family of dual specificity phosphatases.
Two isoforms of cdc25, cdc25B, and cdc25C, appear to be re-
sponsible for activating cdc2/cyclin B in mitosis (3–5). In vivo,
cdc25B is active during G2 phase, before cdc25C is activated at
the G2/M transition (4, 6, 7), and cdc25B is more efficient than
cdc25C at promoting mitosis (8, 9). This correlates with the in
vitro activity of cdc25B and cdc25C, with the unmodified form
of cdc25B able to efficiently activate the cyclin B1/cdc2 kinase
complex, whereas only the hyperphosphorylated form of
cdc25C efficiently catalyzed this activation (4). Overexpression
of dominant-negative mutants of cdc25B and cdc25C results in
a G2 phase arrest. However, whereas cdc25B dominant-nega-
tive overexpression blocked all evidence of mitosis, cells over-
expressing the cdc25C dominant-negative mutant often dis-
played evidence of mitotic events in the cytoplasm, with a
complete block in nuclear mitotic events (3). These data point
to cdc25B as the initiator of mitosis, whereas the role of cdc25C
is to ensure full activation of cdc2/cyclin B and thereby rapid
entry into mitosis.
cdc25B itself is tightly regulated at a number of levels. Mul-
tiple alternatively spliced forms of cdc25B are expressed, al-
though only the two variants, cdc25B2 and cdc25B3, are ex-
pressed as detectable levels of protein (10, 11). Its protein levels
are tightly controlled, accumulating in early G2 phase and
destroyed by proteasome-mediated destruction during early
mitosis (12). It accumulates in the nucleus in early G2 phase,
but at prophase it translocates to cytoplasm, and its appear-
ance in this compartment is tightly associated with the activa-
tion of cdc2/cyclin B1 in the cytoplasm and the appearance of
cytoplasmic mitotic features such as increased microtubule
nucleation at the centrosome and changes in microtubule dy-
namics (3, 6). cdc25B is responsible for the activation of not
only cdc2/cyclin B1 at prophase, but also appears to control
activation of the G2 phase pool of cdk
12/cyclin A during G2
phase when cdc25B is localized in the nucleus (4, 6, 9). In
normal early G2 phase and in G2 phase checkpoint arrested
cells, the nuclear localized cdc25B is held in an inactive form as
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its substrate cdk2/cyclin A is also maintained in its Tyr-15-
phosphorylated inactive form.
The mechanism regulating activity and localization of
cdc25B involves the binding of 14-3-3 proteins to cdc25B. The
14-3-3 proteins are a highly conserved family of proteins that
have important roles in a wide range of cell signaling, cell cycle,
and survival pathways (reviewed in Refs. 13 and 14). The
14-3-3 proteins bind to specific phosphoserine-containing mo-
tifs (15), and their dimeric nature allows them to act as intra-
and intermolecular, phosphorylation-dependent adaptors (13,
16). 14-3-3 binding is a highly conserved mechanism, impli-
cated in the regulation of cdc25 function in organisms from
yeast to humans (17, 18). cdc25B has a major 14-3-3 binding
site at Ser-323, and mutation of this residue to a nonphospho-
rylatable residue that does not support 14-3-3 binding results
in changes in cdc25B localization and increased cdc25B activity
(19, 20). The Ser-323 site is the target for p38MAPK following
UV irradiation, which results in stabilizing 14-3-3 binding and
blocking entry into mitosis (21). Thus the factors that control
14-3-3 binding are likely to be important regulators of both
normal G2/M progression and in the G2 checkpoint control.
The question of how 14-3-3 binding controls cdc25B functions
is not yet fully resolved. The dimeric structure of 14-3-3 sug-
gests it is acting as a molecular adaptor, but to what? Previous
work has suggested that 14-3-3 binding to the Ser-323 site
alone was not sufficient for down-regulating its activity, and
14-3-3 binding to this site cannot explain the prophase cyto-
plasmic translocation to cdc25B. In this study we have further
investigated the mechanism by which 14-3-3 binding controls
cdc25B function. We demonstrate that there are three func-
tional 14-3-3 binding sites, two in the N-terminal regulatory
domain and one in the C-terminal catalytic domain. Loss of
14-3-3 binding to either the N-terminal or C-terminal domains
influences the localization of cdc25B, although mutation of any
of the 14-3-3 binding sites is sufficient to activate cdc25B.
MATERIALS AND METHODS
Cell Culture and Transfections—293H cells (Invitrogen), HeLa, and
COS-1 cells were grown in Dulbecco’s minimal essential medium (In-
vitrogen) supplemented with 10% Serum Supreme (BioWhittaker).
HeLa and COS-1 cells were transfected by electroporation and 293H
cells were transfected using LipofectAMINE 2000 (Invitrogen) follow-
ing manufacturer’s instructions. Transfections were harvested 6–24 h
later for analysis. Leptomycin B, a gift from Dr. M. Yoshida, was added
4 h post-transfection and harvested 8 h for immunofluorescent staining.
Plasmid Constructs and in Vitro 14-3-3 Binding—pGEX cdc25B3
N-terminal was constructed from full-length pGEX cdc25B3 by diges-
tion with BsrG1 and EcoR1 to remove the C terminus, then treated with
DNA polymerase I, large (Klenow) fragment (NEB Biolabs) to fill the
5-sticky ends. The blunt-ended product was recircularized using T4
DNA ligase (NEB Biolabs). The S151A and S230A point mutations were
produced using site-directed mutagenesis kit (Stratagene). The double
mutant, pGEX cdc25B3 S151A/S230A N terminus, was constructed by
subcloning the smaller fragment produced by digesting pGEX cdc25B3
S151A N terminus with NcoI and NotI, into pGEX cdc25B3 S230A N
terminus. A further truncation of cdc25B3 to make pGEX cdc25B3 S49
was constructed by subcloning the BstB1-digested fragment of pGEX
cdc25B3 N terminus into pGEX-2T vector. The GST-cdc25B3 N termi-
nus proteins were expressed in bacteria, purified using glutathione-
agarose and used to examine 14-3-3 binding as described previously
(20). Myc-tagged Cdc25B3 wild type, CR/SK, and S323A mutants were
cloned into the pUCSR mammalian expression plasmid as described
elsewhere (3, 20). The triple mutant, pUCSR cdc25B3 S151A/S230A/
S323A, was constructed by subcloning the smaller fragment produced
by digesting pGEX cdc25B3 S151A/S230A with BamHI and BsrGI, into
pUCSR cdc25B3 S323A. The double mutant, pUCSR cdc25B3 S151A/
S230A, was constructed by subcloning the smaller fragment produced
by digesting pUCSR cdc25B3 S151A/S230A/S323A with BamHI and
BsrGI, into pUCSR cdc25B3. The single mutant, pUCSR cdc25B3
S151A was constructed by subcloning the smaller fragment produced by
digesting pGEX cdc25B3 S151A with BamHI and BsrGI, into pUCSR
cdc25B3. The single mutant, pUCSR cdc25B3 S230A was constructed
by subcloning the smaller fragment produced by digesting pGEX
cdc25B3 S230A with BamHI and BsrGI, into pUCSR cdc25B3. The
Myc-tagged 14-3-3 zeta was produced by subcloning 14-3-3 zeta (a gift
from Dr. M. Yaffe) into pUCSR-Myc. Constructs expressing GST-
14-3-3 zeta wild-type and dimerization mutants were gifts from
Dr. Y. Tzivion.
Immunoblotting and Immunoprecipitation—Cells were lysed in 14-
3-3 lysis buffer (Tris, pH 7.5, 50 mM; NaCl, 150 mM; EGTA, 2 mM;
MgSO4, 2 mM; Tween 20, 0.1%; dithiothreitol, 5 mM), and a small
fraction removed for immunoblotting. The remainder was immunopre-
cipitated overnight at 4 °C with either anti-cdc25B antibody (3) or
anti-Myc tag antibody (9B11, Cell Signaling). The antibody complexes
were precipitated with 20 l of a 50% slurry of protein A-Sepharose
(Amersham Biosciences) washed four times with 14-3-3 lysis buffer and
eluted with SDS sample buffer. GST-14-3-3 zeta expressed in HeLa
cells was affinity-purified from similarly prepared lysates using gluta-
thione-agarose and eluted with SDS sample buffer. Samples were re-
solved on 10% SDS-PAGE, transferred to nitrocellulose membranes and
immunoblotted with either anti-Myc tag, anti-cdc25B, anti-GST, anti-
cdc2, anti-pan 14-3-3 or anti-cyclin B1 antibodies (3), detected using
ECL (PerkinElmer Life Sciences).
Immunofluorescent Staining—293H cells grown on glass coverslips
overnight were transfected and washed once with PBS at 8–24 h
post-transfection. Asynchronously growing or etoposide-treated, G2
phase arrested Hela cells were transfected and plated onto glass cov-
erslips. Cells were washed once with PBS at 8 h post-transfection. Cells
were then fixed with 20 °C methanol and stored overnight at 20 °C
until required. For immunostaining, cells were washed with PBS, then
rehydrated with PBS containing 0.1% Tween 20, 0.05% sodium azide,
and 3% bovine serum albumin for 30 min at room temperature. Cells
were stained with primary antibody, mouse anti--tubulin (1:1000,
Sigma Aldrich), and rabbit anti-Cdc25B (1:200, Santa Cruz Biotechnol-
ogy), for 1 h at room temperature in 3% bovine serum albumin. The
coverslips were washed four times in PBS containing 0.1% skim milk
powder for 5 min, and cells were stained with fluorophore-conjugated
secondary antibody/anti-mouse Cy3 (1:200, Zymed Laboratories Inc.)
and anti-rabbit FITC (1:200, Silenus), and the DNA was stained with
either 1 g/ml propidium iodide or 10 g/ml DAPI for 1 h at room
temperature. The coverslips were washed again as above and mounted
onto microscope slides using Vecta Shield to preserve fluorescence.
Gel Filtration Analysis—293H and HeLa cells were transfected with
either pUCSR-Myc Cdc25B3 wild type, S323A, or triple mutant, then
harvested 8 h post-transfection, and cell pellets were stored at 80 °C
until required. Cells were lysed in 300 l of 14-3-3 lysis buffer and
precleared by centrifuging the lysate twice at 12,000 rpm for 15 min in
a microcentrifuge at 4 °C before loading onto the Superose 12 column
(Amersham Biosciences). The column was equilibrated in 14-3-3 buffer
(without Tween 20) and eluted at a flow rate of 300 l/min. 300-l
fractions were collected after an initial volume of 7 ml. Protein fractions
were precipitated overnight in 4 volumes of acetone at 80 °C and
proteins pelleted by centrifugation at 12,000 rpm for 30 min in a
microcentrifuge. Pellets were dissolved in SDS sample buffer and pro-
teins resolved by SDS-PAGE, transferred to nitrocellulose membranes,
and immunoblotted for cdc25B and 14-3-3.
RESULTS
Identification of cdc25B N-terminal 14-3-3 Binding Sites—
Previously, we have found that mutation of the Ser-323 site on
cdc25B resulted in a dramatic reduction in 14-3-3 binding,
although not a complete loss (20). This suggested that there
were other sites capable of supporting 14-3-3 binding. Our data
had also suggested that 14-3-3 binding to Ser-323 alone was
insufficient to explain the regulation of cdc25B activity, but
that this also involved the N-terminal regulatory domain. To-
gether these findings suggested that there were important
regulatory 14-3-3 binding sites in the N-terminal domain of
cdc25B. This region contains three sequences that conform to
the consensus, phosphorylation-dependent 14-3-3 binding site,
RX1–2SPXP (Fig. 1A). To identify which of these sites were
capable of supporting 14-3-3 binding in vitro, bacterially ex-
pressed GST-cdc25B3 N-terminal protein fragments (residues
1–311 of cdc25B3, Ref. 3) were produced with point mutations
of the Ser residues Ser-151 and Ser-230 changed to Ala, either
individually or in tandem, and a truncation of the N terminus
that included only the Ser-49 site deleting the Ser-151 and
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Ser-230 sites (Fig. 1B). The GST fusion proteins were incu-
bated in HeLa cell extracts, or extracts supplemented with
MgSO4 or MgSO4 and ATP to support phosphorylation. 14-3-3
binding was detected by immunoblotting. The wild-type N-
terminal sequence bound 14-3-3 in the presence of Mg2 and
ATP, and the individual S151A and S230A mutants retained
Mg2/ATP-dependent 14-3-3 binding, albeit a reduced level,
whereas the double S151/230A mutant bound only background
levels of 14-3-3, which did not increase with the addition of
Mg2/ATP (Fig. 2A). The Ser-49 only containing truncation
also bound only background levels of 14-3-3, which was insen-
sitive to Mg2/ATP addition, demonstrating that this site was
incapable of supporting 14-3-3 binding. Thus only the Ser-151
and Ser-230 sites are viable 14-3-3 binding sites.
To examine the utilization of the in vitro identified 14-3-3
binding sites in vivo, HeLa cells were transfected with Myc-
tagged cdc25B3 wild type and versions containing individual
14-3-3 binding sites mutations including the originally identi-
fied Ser-323 site, tandem mutation of the Ser-151 and Ser-230
sites, and mutation of all three sites (triple), together with
Myc-tagged 14-3-3 zeta. Cdc25B3 was used as it is the major
spliced form of cdc25B expressed and all the 14-3-3 binding
sites are completely conserved in all cdc25B splice variants
(11). Lysates prepared from the transfected cells were immu-
noprecipitated with an anti-cdc25B antibody, and the immuno-
precipitates were analyzed for cdc25B and Myc-14-3-3 binding.
The S323A mutant displayed severely reduced 14-3-3 binding
compared with wild-type protein, whereas individual Ser-151
and Ser-230 mutants displayed wild-type levels. The Ser-151
Ser-230 double mutant displayed a 50% decrease in binding,
and the triple mutant did not bind 14-3-3 (Fig. 2B). This con-
firms Ser-151 and Ser-230 are in vivo 14-3-3 binding sites,
although they appeared to be mutually redundant, with a sig-
nificant reduction in 14-3-3 binding only observed with muta-
tion of both these sites. The complete loss of 14-3-3 binding in
the triple mutant confirmed Ser-151, Ser-230, and Ser-323 as
the only 14-3-3 binding sites in cdc25B.
Mutation of N-terminal 14-3-3 Binding Sites Activate
cdc25B—We have previously shown that S323A mutation is
sufficient to activate cdc25B (20). However, deletion of the
N-terminal domain was also activating, suggesting that 14-3-3
binding to the Ser-323 site was interacting with the N-terminal
domain to regulate cdc25B activity. The dimeric structure of
14-3-3 suggested that the 14-3-3 dimer binding to Ser-323 could
interact with 14-3-3 binding sites in the N-terminal domain.
This model would predict that mutation of the N-terminal
14-3-3 binding sites should also be activating mutations. To
test this, substrate trapping mutants of cdc25B (cdc25B CR/SK
mutations, Refs. 20) incorporating 14-3-3 binding site muta-
tions, S323A, the tandem S151A/S230A N-terminal site muta-
tions, or the triple mutant, were expressed in 293H cells. The
cdc25B immunoprecipitates were immunoblotted for cdc25B
and bound cdc2/cyclin B1 substrate. All the 14-3-3 binding site
mutants displayed high levels of cdc2/cyclin B1 binding com-
pared with equivalent levels of cdc25B2 and cdc25B3 with
wild-type 14-3-3 binding sites, indicating that tandem muta-
tion of the N-terminal 14-3-3 binding sites was sufficient to
activate cdc25B (Fig. 3A). The activity of the cdc25B 14-3-3
binding site mutants was also assessed by their relative ability
to activate endogenous cdc2/cyclin B1 when transiently over-
expressed in etoposide-treated, G2 phase-arrested HeLa cells
(20). This assay demonstrated that the individual site mutants
were activating mutations with similar activity to the S323A
mutant, and increased activity compared with the wild-type
protein, supporting the assignment of these mutations as acti-
vating mutations (Fig. 3B). Interestingly, the tandem S151A/
S230A mutant and triple mutant had increased activity com-
pared with individual site mutants, suggesting that mutation
of individual sites was not sufficient to completely abrogate the
regulatory effect of 14-3-3 binding. The ability of the overex-
pressed cdc25B to force etoposide-arrested G2 phase cells into
mitosis was also assessed by counting the number of cdc25B
overexpressing cells displaying a mitotic phenotype at 8 h after
transfection. All the 14-3-3 binding site mutants had similar
FIG. 1. Consensus 14-3-3 binding sites in cdc25B. A, the consen-
sus 14-3-3 binding site (in italics, the phosphorylated Ser residue has an
asterisk) aligned with the three potential sites in the cdc25B N-terminal
domain. B, schematic representation of cdc25B3 sequence showing the
relative positions of the potential 14-3-3 binding sites, the NES, NLS,
and the alternatively spliced exon. The relative positions of the trun-
cations produced by BstB1 and BsrG1 digestion of the full-length
cdc25B3 cDNA are shown.
FIG. 2. Identification of the 14-3-3 binding sites in cdc25B. A,
bacterially expressed GST fusion products of cdc25B3 N-terminal do-
main (residues 1–311), either wild type (wt), individual S151A and
S230A mutants, the tandem S151A/S230A mutant, and the N-terminal
truncation containing only the Ser-49 site were used to examine the in
vitro binding of 14-3-3. The glutathione-agarose-bound GST fusion
products were incubated in HeLa cell lysates supplemented as indi-
cated, washed then analyzed by immunoblotting with an anti-GST
antibody to show the levels of the GST-N-terminal fusion proteins, and
with a pan isoform 14-3-3 antibody to terminal bound 14-3-3. B, HeLa
cells were transfected with either empty vector (vec), cdc25B3 wild type
(wt), or the indicated 14-3-3 binding site mutant, without or with
myc-14-3-3 zeta, then harvested after 8 h. Lysates of these cells were
immunoprecipitated with anti-cdc25B, and lysates (as input control)
and immunopreciptates were immunoblotted for Myc-tagged cdc25B
and 14-3-3 zeta.
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ability to force cells into mitosis, although in this measure the
individual Ser-151 and Ser-230 had slightly lower activity than
the other mutants (Fig. 3C).
14-3-3 Acts as an Intramolecular Bridge to Regulate cdc25B
Activity—The finding that disruption of either N-terminal or
C-terminal 14-3-3 binding sites on cdc25B was sufficient to
activate its phosphatase activity suggested that loss of binding
to either the N-terminal or C-terminal domains of the protein
was sufficient to permit increased access of the substrate to the
catalytic site of the enzyme. This was demonstrated directly
with the increased cdc2/cyclin B1 binding to the substrate-
trapping mutants (Fig. 3A). The apparent equivalence of the
14-3-3 binding sites in terms of their ability to regulate cdc25B
activity was difficult to reconcile with the very different conse-
quences of the mutations on 14-3-3 binding. One plausible
explanation was that the dimeric 14-3-3 molecule was acting as
an intramolecular bridge, and thus loss of binding from either
the N- or C-terminal sites resulted in the disruption of the
bridge and increased access to the catalytic site of cdc25B.
Another possible model was that dimeric 14-3-3 was acting as
an adaptor linking two molecules of cdc25B, with two 14-3-3
dimers linking the cdc25B in a head-to-tail fashion to bring the
catalytic domain of one cdc25B in close contact with the regu-
latory domain of the second cdc25B. To examine whether 14-
3-3 was acting as an intra- or intermolecular bridge, cells
overexpressing cdc25B3 wild type, S232A, or the triple mutant
were analyzed by gel filtration chromatography on a Superose
12 column. Wild-type cdc25B3 eluted as a broad peak with a
shoulder eluting with an apparent molecular size of 120 kDa
whereas the S323A mutant eluted with an apparent molecular
size of 80 kDa (Fig. 4). cdc25B3 has an apparent molecular
mass of 75 kDa determined by SDS-PAGE despite its calcu-
lated molecular mass of only 62 kDa (3). In a number of sepa-
rate experiments, the proportion of cdc25B3 wild type eluting
in the 120 and 80 kDa size ranges was variable, but in all
experiments wild-type cdc25B3 eluted across this molecular
size range. By contrast, the S323A mutant always eluted as
single peak of 80 kDa. The triple mutant behaved identically to
the S323A mutant (data not shown) indicating that the loss of
14-3-3 binding was likely to be responsible for the reduced
molecular size of these mutants.
When similar fractions were immunoblotted for 14-3-3 using
as a pan isoform antibody, the major peak of 14-3-3 eluted with
a molecular size of 50 kDa, the expected size of the 14-3-3
dimer, although low levels of 14-3-3 were detected across all
fractions. The 120-kDa shoulder of cdc25B3 wild type corre-
sponds to the approximate size of monomeric cdc25B and a
dimer of 14-3-3, making it unlikely that 14-3-3 was bridging
two molecules of cdc25B. Moreover, it was unlikely that cdc25B
was complexed with an unidentified protein via a 14-3-3 dimer,
although the possibility of a small proportion of cdc25B doing
so, or this protein having a low molecular weight and therefore
difficult to detect by this analysis, cannot be discounted.
FIG. 3. Mutation of 14-3-3 binding sites activate cdc25B. A,
293H cells were transfected with either empty vector (vec) or substrate-
trapping mutants of cdc25B2 (B2), cdc25B3 (B3), or substrate-trapping
version of cdc25B3 containing the indicated 14-3-3 binding site muta-
tions. Anti-cdc25B immunoprecipitates were immunoblotted for cdc25B
and the bound cyclin B1 and cdc2. B, etoposide-treated, G2 phase-
arrested HeLa cells were transfected with either empty vector, catalyt-
ically inactive (CR/SK), wild type (WT), or indicated 14-3-3 binding site
mutant of cdc25B3. Cells were harvested after 8 h and the activity of
the endogenous cdc2/cyclin B1 assayed as a measure of cdc25B activity.
Data are expressed as percentage increase over the inactive cdc25B3
CR/SK mutant and represent the mean and S.D. from at least three
independent experiments. C, etoposide-treated HeLa cells, transfected,
and harvested as in B, were fixed and immunostained for cdc25B,
-tubulin, and DNA. The percentage of cdc25B-overexpressing cells
displaying a mitotic phenotype was counted. For each condition at least
100 cdc25B3-overexpressing cells were counted. The data represent the
mean and S.D. from three independent experiments.
FIG. 4. Cdc25B is only associated with dimeric 14-3-3. A, HeLa
cells transfected with either cdc25B3 wild type (25B3 wt) or the S323A
mutant were fractionated on a Superose 12 gel filtration column. Frac-
tions collected were immunoblotted for cdc25B and 14-3-3 with a pan
14-3-3 isoform antibody. The apparent molecular size of the peak frac-
tions and the elution position of bovine serum albumin and ovalbumin
(66 and 43 kDa markers) are shown. These data are typical of at least
three independent experiments. B, densitometry of the levels of cdc25B
detected in the immunoblots shown in A.
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The model of 14-3-3 acting as an intramolecular bridge would
predict that 14-3-3 mutants that are defective in dimerizing
should increase access of the cdk/cyclin substrates to the active
site of cdc25B, thereby increasing its phosphatase activity. This
was directly tested using the GST-14-3-3 zeta dimerization
mutant used previously to demonstrate that the 14-3-3 dimer
was essential to regulate Raf-1 activity (22). The zeta isoform of
14-3-3 has been demonstrated to be a preferred binding partner
of cdc25B (23). When wild-type GST-14-3-3 zeta was co-ex-
pressed with wild-type cdc25B3 substrate trapping mutant, the
level of bound cdc2/cyclin B1 was below the level associated
with either cdc25B transfected alone or transfected with the
dimerization mutant of 14-3-3 zeta (Fig. 5A). Although the
dimerization mutant was expressed at a similar level to the
wild type GST-14-3-3 zeta, it bound cdc25B with lower avidity
than the wild-type protein, demonstrated by the lower level of
cdc25B3 associated with the GST-14-3-3 proteins in glutathi-
one bead pull-down analysis, despite similar levels of cdc25B3
being expressed in these cells (Fig. 5, B and C). These data
suggest that the GST-14-3-3 dimerization mutant effectively
reduced 14-3-3 binding to cdc25B, thereby increasing access to
the catalytic site.
14-3-3 Binding Regulates cdc25B Localization—The localiza-
tion of endogenous cdc25B changes during the cell cycle, accu-
mulating in the nucleus during late S and G2 phase, then
relocating to the cytoplasm at prophase just prior to nuclear
envelope breakdown (3, 6). The question of what regulates this
change in localization is still poorly understood, although loss
of 14-3-3 binding to the Ser-323 site resulted in a complete loss
of cytoplasmic localization (19). cdc25B contains a functional
nuclear export sequence (NES) located in the N terminus of the
protein between residues 28 and 40 (19). The Ser-323 14-3-3
binding site is proximal to the nuclear localization sequence
(NLS). Although the NES is close to the N terminus of the
protein, the N-terminal 14-3-3 binding sites may influence
access to this sequence (Fig. 1B). The localization of cdc25B3
14-3-3 binding site mutants was examined in asynchronously
growing HeLa cells 8 h after transient transfection, when the
majority of transfected cells were still in G1 or S phase. The
localization of the wild-type protein was predominantly nuclear
or nuclear and cytoplasmic, whereas the S323A and triple
mutants where exclusively nuclear (Fig. 6, A and B). Interest-
ingly, mutation of either Ser-151 or Ser-230 individually or in
tandem caused a striking increase in strictly cytoplasmic local-
ization of cdc25B, the tandem mutations giving a slightly
higher proportion of cells with cytoplasmic localization than
the individual mutants. The loss of the Ser-323 14-3-3 binding
site appeared to have a dominant effect over the cytoplasmic
FIG. 5. Dimeric 14-3-3 binding to cdc25B blocks substrate ac-
cess to the catalytic site. COS-1 cells were transfected with either
empty vector (vec), or the substrate-trapping version of cdc25B3 wild
type, and co-transfected with either empty vector, GST-14-3-3 zeta wild
type (wt) or dimerization mutant (dm). A, anti-cdc25B immunoprecipi-
tates were immunoblotted for cdc25B and bound substrate cdc2 and
cyclin B1. B, the level of GST-14-3-3 zeta and associated cdc25B was
determined by glutathione-agarose precipitation and immunoblotting
for the GST-14-3-3 and cdc25B. C, lysates from the transfections were
immunoblotted for the overexpressed cdc25B. These data were typical
of three independent experiments.
FIG. 6. Mutation of 14-3-3 binding sites changes localization of
cdc25B. A, immunofluorescent micrographs of HeLa cells overexpress-
ing cdc25B3 S151A/S230A (top and middle) and cdc25B3 triple mutant
(bottom). Cells were stained for cdc25B and propidium iodide (PI) for
DNA and demonstrate the three localizations of cdc25B, cytoplasmic
(top), nuclear and cytoplasmic (middle), nuclear (bottom). B, HeLa cells
transfected with the indicated cdc25B3 were fixed after 8 h, immuno-
stained as in A and the localization of cdc25B quantitated. The data
represent at least 100 cdc25B overexpressing cells in each transfection
and are the mean and S.D. of three independent experiments. Similar
data were obtained with transfection into 293H cells (data not shown).
C, 293H cells transfected with cdc25B3 S151A/S230A were treated
either without or with leptomycin B for 4 h. Cells were then fixed and
stained as in A. Leptomycin B treatment caused the complete relocal-
ization of cdc25B into the nucleus.
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localization resulting from mutation of the N-terminal 14-3-3
binding sites, with the triple mutant localizing almost exclu-
sively to the nucleus similar to the S323A mutant.
The cytoplasmic localization caused by the N-terminal site
mutations may have been a consequence of either a loss of NLS
function or an increased nuclear export due to increased influ-
ence of the N-terminal NES. To differentiate between these
possibilities, the effect of the nuclear export inhibitor leptomy-
cin B on cdc25B3 S151/230A tandem mutant localization was
examined. Whereas normally 70% of cells expressing this
mutant displayed only cytoplasmic or cytoplasmic and nuclear
accumulation of the protein, after 4 h of leptomycin B treat-
ment 100% of cells displayed only nuclear staining for this
mutant (Fig. 6C). Thus the cytoplasmic localization was a con-
sequence of increased influence of the N-terminal NES over the
C-terminal NLS.
These data provide evidence that the binding of 14-3-3 to
different sites on cdc25B strongly influences the cellular local-
ization of the protein. However, the localization of cdc25B may
not be solely controlled by site-specific 14-3-3 binding. When
the 14-3-3 binding site mutants were expressed in etoposide-
treated, G2 phase arrested HeLa cells, a significant change in
cellular localization was observed when compared with the
transfections into asynchronously growing cells, which were
predominantly G1 and S phase. Wild type and all mutants
displayed a higher level of cytoplasmic localization, both cyto-
plasmic only and cytoplasmic and nuclear, when expressed in
etoposide-treated cells (Fig. 7A) compared with the asynchro-
nous cultures (Fig. 6B). This was particularly evident with the
S323A and triple mutants, which were almost exclusively nu-
clear in the asynchronous cultures but displayed significant
levels of cytoplasmic expression when expressed in the etopo-
side-treated cells. Interestingly, this contrasted with endoge-
nous cdc25B, which displayed exclusively nuclear staining in
the same cultures (Fig. 7B). The increased cytoplasmic staining
may be a consequence of the overexpressed cdc25B pushing the
etoposide-treated, G2 arrested cells into mitosis, and the high
proportion of mitotic cells detected in all the mutant cdc25B-
overexpressing cultures (Fig. 7A). The cdc25B wild-type-over-
expressing cells also displayed an increased cytoplasmic stain-
ing for cdc25B, even though few mitotic cells were detected.
Wild-type cdc25B is a weaker activator of endogenous cdc2/
cyclin B than the mutants (Fig. 3, A and B), but it will even-
tually overcome arrest and cause cells to undergo mitosis (20).
Thus wild-type cdc25B3-overexpressing cells are also transit-
ing into mitosis, albeit slower than the mutants. The increased
cytoplasmic localization suggests that there are other factors
acting during progression through G2 into mitosis that influ-
ence cdc25B cytoplasmic localization, probably cooperating
with 14-3-3 binding to regulate its cytoplasmic localization at
the G2/M transition.
DISCUSSION
Here we have demonstrated that cdc25B activity is regulated
by the binding to 14-3-3. Cdc25B contains three functional
14-3-3 binding sites Ser-151, Ser-230, and Ser-323, and muta-
tion of all these sites to the nonphosphorylatable Ala residue is
required to completely abrogate 14-3-3 binding to cdc25B. The
Ser-323 site is highly conserved between human cdc25B and
cdc25C, and is also conserved in all mammalian cdc25B se-
quences. The Ser-230 site is also well conserved among mam-
malian cdc25B sequences whereas the Ser-151 site is poorly
conserved, indicating that all mammalian cdc25Bs possess
functional N- and C-terminal domain 14-3-3 binding sites.
The model for 14-3-3 binding and regulation of cdc25B activ-
ity must account for the dimeric nature of 14-3-3, the presence
of functional 14-3-3 binding sites in the N- and C-terminal
domains of cdc25B, the finding that all 14-3-3 site mutations
are activating mutations, the ability of the dimerization mu-
tant to increase accessibility to the active site of cdc25B, and
the molecular size of the cdc25B complex suggesting the pres-
ence of only a cdc25B monomer and a 14-3-3 dimer. We propose
that 14-3-3 is acting as an intramolecular bridge, constraining
the N-terminal in such a way that it blocks access of the
substrate cdk/cyclins to the catalytic site in the C-terminal
domain of cdc25B when bound to both N- and C-terminal 14-3-3
binding sites (Fig. 8A). Loss of the bidentate binding results in
a relaxation of cdc25B structure and increased access to the
catalytic site (Fig. 8, B and C). This model is similar to that
proposed for the regulation of Raf-1 activity (22) in which
FIG. 7. An additional factor influences cd25B cytoplasmic lo-
calization in G2/M. A, etoposide-treated HeLa cells were transfected
with the indicated cdc25B3 mutants and fixed after 8 h. Cells were
immunostained for overexpressed cdc25B, and the localization of
cdc25B or whether the cell displayed a mitotic phenotype was quanti-
tated as in Fig. 7. The data represent the mean and S.D. from three
experiments. B, the localization of endogenous cdc25B in an untrans-
fected cell in an etoposide-treated HeLa cell culture. The endogenous
protein was localized to the nucleus.
FIG. 8. Model for the regulation of cdc25B activity and local-
ization by dimeric 14-3-3 binding. Cdc25B is held in an inactive
state by dimeric 14-3-3 forming an intramolecular bridge from the
major Ser-323 site to either of the N-terminal sites which are in equi-
librium (A). Mutation of the Ser-323 site, which is equivalent to the
triple mutant in terms of 14-3-3 binding results in increased access to
the catalytic site (HCXXXXXR) as well as the NES and NLS. The NLS
must be dominant resulting in nuclear localization (B). Mutation of the
N-terminal sites has little effect on 14-3-3 binding to Ser-323 but results
in opening up of the structure permitting increased access to the cata-
lytic site and the NES. 14-3-3 binding to the Ser-323 site must hinder
access to the NLS resulting in dominance of the NES (C).
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14-3-3 binds to inactive Raf-1 at Ser-259 and Ser-621 to main-
tain it in an inactive state, and disruption of either Ser-259 or
Ser-621 binding is sufficient to permit activation of Raf-1 (24).
This model of dimeric 14-3-3 binding to cdc25B N- and C-
terminal domains supports the “molecular anvil” model for
14-3-3 proposed by Yaffe (25). cdc25B clearly has a high affinity
14-3-3 binding site, the Ser-323 site. Loss of the N-terminal
14-3-3 binding sites have only a small effect on 14-3-3 binding
whereas loss of the Ser-323 site results in a severe reduction in
binding. The Ser-151 and Ser-230 sites appear to cooperate in
binding 14-3-3 anchored to the Ser-323 site, and even though
mutation of a single N-terminal site had little effect on 14-3-3
binding to cdc25B, the single mutants had similar activity as
the S151A/S230A tandem mutant, evidence that loss of a single
N-terminal site was sufficient to destabilize the intramolecular
bridge and open the structure of cdc25B to increase accessibil-
ity to the catalytic site. In this model, 14-3-3 anchored to the
Ser-323 high affinity sites is in a binding equilibrium between
the Ser-151 and Ser-230 sites (Fig. 8A). Thus loss of a single
N-terminal site pushes the equilibrium toward the more open
conformation, although loss of both sites further increases the
likelihood of the open conformation.
14-3-3 binding also influences cdc25B localization. It has
been previously shown that mutation of Ser-323 causes cdc25B
to localize strictly to the nucleus (19). Here we have shown that
mutation of either N-terminal 14-3-3 binding site increases the
cytoplasmic localization of cdc25B. The proximity of the NLS to
the Ser-323 site and NES to the N-terminal sites suggests that
the binding of 14-3-3 to these sites influences the accessibility
of transport chaperones to these sequences (Fig. 1B). Loss of
14-3-3 binding to Ser-323 site would appear to increase access
to the NLS, increasing the localization of this mutant protein to
the nucleus as observed (Fig. 8B). Loss of 14-3-3 binding to the
N-terminal sites, which has little effect on 14-3-3 binding to the
Ser-323 site, indicated by the high level of 14-3-3 binding to
even the S151A/S230A tandem mutant, must increase access to
NES in the N-terminal domain and perhaps the 14-3-3 binding
to the Ser-323 site inhibits access to the NLS, resulting in an
increased export from the nucleus (Fig. 8C). Complete loss of
14-3-3, or mutation of only the Ser-323 site favors nuclear
import and retention. The wild-type protein shows a predomi-
nantly nuclear only or nuclear and cytoplasmic localization,
suggesting that the conformation of the cdc25B with bidentate
14-3-3 binding favors nuclear import and retention, although
some shuttling is likely to occur. However, the observation that
as cells progress through G2 phase into mitosis, even the
strictly nuclear S323A and triple mutants display increased
cytoplasmic localization is evidence that other factors also reg-
ulate cdc25B localization. It is likely that the extensive mitotic
phosphorylation of the N-terminal domain is involved, which
may influence 14-3-3 binding to the N-terminal sites and per-
haps localization by other mechanisms. A recent report has
demonstrated that Ser-146 in the cdc25B1 splice variant
(equivalent to Ser-160 in the cdc25B3 sequence) is phosphoryl-
ated in mitosis, and mutation of this site to Gly resulted in the
increase cytoplasmic localization of the mutant protein (26).
Phosphorylation at the Ser-160 site might influences 14-3-3
binding to the Ser-151 14-3-3 binding site, although it would
seem more probable that phosphorylation at this site would
inhibit 14-3-3 binding and thereby cause the cytoplasmic local-
ization. These authors have demonstrated that other phospho-
rylations of the N-terminal domain occur, and these may also
influence 14-3-3 binding to the N-terminal of cdc25B and its
cytoplasmic export.
The regulation and utilization of the N-terminal 14-3-3 bind-
ing sites may also vary for the individual cdc25B splice vari-
ants. The Ser-151 site is immediately adjacent to the exon
spliced out of the cdc25B2 variant (Fig. 1B), which may effect
the utilization of this in the B2 variant. The exon contains the
Ser-160, and Ser-186 and Ser-187 sites phosphorylated by cdc2/
cyclin B and casein kinase 2, respectively (26, 27), suggesting
that the regulation of the Ser-151 site in cdc25B2 is likely to be
different from the other cdc25B variants.
In this report we have demonstrated that the activity and
localization of cdc25B is regulated by the binding of a dimer of
14-3-3 to sites in the N- and C-terminal domains of the protein,
acting as an intramolecular bridge to constrain the protein
such that access to the catalytic site is restricted as is access to
the NES. The loss of 14-3-3 binding to any of the sites on
cdc25B is sufficient to activate the protein, but loss of binding
to the N-terminal or C-terminal domains results in increased
nuclear export and nuclear localization, respectively. The ki-
nases that phosphorylate these 14-3-3 binding sites will be
important regulators of cdc25B activity, but perhaps more im-
portantly, the factors that disrupt binding to the N- and C-
terminal sites will be critical activators of cdc25B. It is likely
that different factors will regulate the disruption of N- and
C-terminal 14-3-3 binding as the outcomes in terms of localiza-
tion of the protein are very different. It would be expected that
loss of binding to the C-terminal domain occurs during G2
phase resulting in the activation of cdc25B while retaining it in
the nucleus to activate the G2 phase pool of cdk2/cyclin A,
whereas cytoplasmic localization of cdc25B in prophase is
likely to involve the disruption of only the N-terminal binding
sites. The loss of binding to these sites may not necessarily
involve dephosphorylation of the binding site serine residues.
In Raf-1 activation, a major role of Ras is to disrupt binding to
14-3-3 to the phosphorylated Ser-259 site (22). Although it is
unlikely that a similar protein interaction will be involved, the
mechanism for disruption of this influential binding event is at
present unknown. Once the 14-3-3 binding is disrupted then
phosphatases may dephosphorylate the 14-3-3 binding sites.
The demonstration that p38MAPK is able to phosphorylate the
Ser-323 site in response to ultraviolet radiation insult is evi-
dence that this site must be dephosphorylated at some stage in
G2/M progression. Although the timing of these events and the
identity of the factors involved are still to be defined, it is clear
from the evidence presented here that regulation of 14-3-3
binding to the N- and C-terminal sites in cdc25B is a major
mechanism regulating cdc25B function.
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